Integrated Biomedical Science Graduate Program, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA.
J Biol Chem. 2010 Mar 12;285(11):7957-63. doi: 10.1074/jbc.M109.091603. Epub 2010 Jan 15.
Glycogen synthase kinase-3 (GSK-3) isoforms, GSK-3alpha and GSK-3beta, are serine/threonine kinases involved in numerous cellular processes and diverse diseases, including Alzheimer disease, cancer, and diabetes. GSK-3 isoforms function redundantly in some settings, while, in others, they exhibit distinct activities. Despite intensive investigation into the physiological roles of GSK-3 isoforms, the basis for their differential activities remains unresolved. A more comprehensive understanding of the mechanistic basis for GSK-3 isoform-specific functions could lead to the development of isoform-specific inhibitors. Here, we describe a structure-function analysis of GSK-3alpha and GSK-3beta in mammalian cells. We deleted the noncatalytic N and C termini in both GSK-3 isoforms and generated point mutations of key regulatory residues. We examined the effect of these mutations on GSK-3 activity toward Tau, activity in Wnt signaling, interaction with Axin, and GSK-3alpha/beta Tyr(279/216) phosphorylation. We found that the N termini of both GSK-3 isoforms were dispensable, whereas progressive C-terminal deletions resulted in protein misfolding exhibited by deficient activity, impaired ability to interact with Axin, and a loss of Tyr(279/216) phosphorylation. Our data predict that small molecules targeting the divergent C terminus may lead to isoform-specific GSK-3 inhibition through destabilization of the GSK-3 structure.
糖原合酶激酶-3(GSK-3)同工型,GSK-3α和 GSK-3β,是参与许多细胞过程和多种疾病的丝氨酸/苏氨酸激酶,包括阿尔茨海默病、癌症和糖尿病。GSK-3 同工型在某些情况下具有冗余功能,而在其他情况下则表现出不同的活性。尽管对 GSK-3 同工型的生理作用进行了深入研究,但它们不同活性的基础仍未解决。对 GSK-3 同工型特异性功能的机制基础有更全面的了解,可能会导致开发同工型特异性抑制剂。在这里,我们描述了哺乳动物细胞中 GSK-3α和 GSK-3β的结构-功能分析。我们删除了两种 GSK-3 同工型的非催化 N 和 C 末端,并生成了关键调节残基的点突变。我们研究了这些突变对 GSK-3 对 Tau 的活性、Wnt 信号转导中的活性、与 Axin 的相互作用以及 GSK-3α/β Tyr(279/216)磷酸化的影响。我们发现,两种 GSK-3 同工型的 N 末端都是可有可无的,而 C 末端的渐进性缺失导致活性缺陷、与 Axin 相互作用能力受损以及 Tyr(279/216)磷酸化丧失的蛋白质错误折叠。我们的数据预测,针对不同 C 末端的小分子可能通过破坏 GSK-3 结构导致同工型特异性 GSK-3 抑制。